SHEILA APARECIDA COELHO SIQUEIRA
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/14 - Laboratório de Investigação em Patologia Hepática, Hospital das Clínicas, Faculdade de Medicina
LIM/14 - Laboratório de Investigação em Patologia Hepática, Hospital das Clínicas, Faculdade de Medicina
10 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 10
conferenceObject Clinical Prognostic Models in Diffuse Large B-Cell Lymphoma Patients Are Still Essential in the Rituximab Era(2014) LAGE, Luis Alberto de Padua Covas; COSTA, Renata Oliveira; HALLACK NETO, Abrahao Elias; SIQUEIRA, Sheila; SANTUCCI, Rodrigo; PAULA, Henrique Moura de; PEREIRA, Juliana- Dealing with bone marrow biopsies in the staging of classical Hodgkin lymphoma: an old issue revisited in the F-18-fluorodeoxyglucose-positron emission tomography era(2015) GONCALVES, Marianne de Castro; PAULA, Henrique Moura de; LINARDI, Camila da Cruz Gouveia; CERCI, Juliano J.; ALDRED, Vera Lucia; SIQUEIRA, Sheila Aparecida Coelho; BUCCHERI, Valeria; ZERBINI, Maria Claudia NogueiraBone marrow biopsy is recommended for staging of classical Hodgkin lymphoma. The aim of this study was to compare bone marrow evaluation by histology with that obtained by F-18-fluorodeoxyglucose-positron emission tomography (FDG-PET). One hundred and three cases of Classical Hodgkin Lymphoma were reviewed. All patients were submitted to FDG-PET evaluation. Bone marrow biopsy results were compared with clinical data and FDG-PET results. Ninety-one cases had available bone marrow biopsies. Overall, there were 16 positive and one suspect case. In five cases, the FDG-PET scan was positive and biopsy was negative: 1/5 was found to correspond to a bone fracture, 3/5 showed marked reactive bone marrow changes and in 1/5 no explanation for the discrepancy was found. FDG-PET showed high sensitivity, supporting the idea that when it is negative, biopsy could be avoided. Care should be taken in patients with a positive FDG-PET, where confirmation by bone marrow biopsy should be recommended.
- Secondary myeloid neoplasms: bone marrow cytogenetic and histological features may be relevant to prognosis(2017) TANIZAWA, Roberta Sandra da Silva; ZERBINI, Maria Claudia Nogueira; ROSENFELD, Ricardo; KUMEDA, Cristina Aiko; AZEVEDO, Raymundo Soares; SIQUEIRA, Sheila Aparecida Coelho; VELLOSO, Elvira Deolinda Rodrigues PereiraAbstract Background: Secondary myeloid neoplasms comprise a group of diseases arising after chemotherapy, radiation, immunosuppressive therapy or from aplastic anemia. Few studies have addressed prognostic factors in these neoplasms. Method: Forty-two patients diagnosed from 1987 to 2008 with secondary myeloid neoplasms were retrospectively evaluated concerning clinical, biochemical, peripheral blood, bone marrow aspirate, biopsy, and immunohistochemistry and cytogenetic features at diagnosis as prognostic factors. The International Prognostic Scoring System was applied. Statistical analysis employed the Kaplan–Meier method, log-rank and Fisher's exact test. Results: Twenty-three patients (54.8%) were male and the median age was 53.5 years (range: 4–88 years) at diagnosis of secondary myeloid neoplasms. Previous diseases included hematologic malignancies, solid tumors, aplastic anemia, autoimmune diseases and conditions requiring solid organ transplantations. One third of patients (33%) were submitted to chemotherapy alone, 2% to radiotherapy, 26% to both modalities and 28% to immunosuppressive agents. Five patients (11.9%) had undergone autologous hematopoietic stem cell transplantation. The median latency between the primary disease and secondary myeloid neoplasms was 85 months (range: 23–221 months). Eight patients were submitted to allogeneic hematopoietic stem cell transplantation to treat secondary myeloid neoplasms. Important changes in bone marrow were detected mainly by biopsy, immunohistochemistry and cytogenetics. The presence of clusters of CD117+ cells and p53+ cells were associated with low survival. p53 was associated to a higher risk according to the International Prognostic Scoring System. High prevalence of clonal abnormalities (84.3%) and thrombocytopenia (78.6%) were independent factors for poor survival. Conclusion: This study demonstrated that cytogenetics, bone marrow biopsy and immunohistochemistry are very important prognostic tools in secondary myeloid neoplasms.
- A difficult case of angioimmunoblastic T-cell lymphoma to diagnose(2016) SACHSIDA-COLOMBO, Elisabetta; MARIANO, Livia Caroline Barbosa; BASTOS, Fernanda Queiróz; RASSI, Amanda Bruder; LAGE, Luís Alberto de Pádua Covas; BARRETO, Ariel; SIQUEIRA, Sheila; PEREIRA, Juliana
- Clinical Outcomes, Prognostic Factors and Therapeutic Management in Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type (ENKTL-NT) - Results of the Multicenter T-Cell Brazil Project(2022) LAGE, Luis Alberto de Padua Covas; MACHADO, Pedro Paulo Faust; REICHERT, Cadiele Oliana; MIRANDA, Eliana C. M. Cristina Martins; CULLER, Hebert Fabricio; SIQUEIRA, Sheila Aparecida Coelho de; COSTA, Renata Oliveira; MIYASHIRO, Denis; SANCHES, Jose; ROCHA, Vanderson; CHIATTONE, Carlos S.; PEREIRA, Juliana
conferenceObject OCT1 gene Expression Is an Independent Prognostic Factor in Diffuse Large B Cell Lymphoma(2014) GOUVEIA, Gisele Rodrigues; FERREIRA, Suzete Cleusa; SIQUEIRA, Sheila; PEREIRA, Juliana- Age >= 75 Years, Clinical Stage III/IV, Neutrophilia and High Lymphocyte/Monocyte Ratio Predict Decreased Overall Survival in Elderly Patients with DLBCL, NOS Older Than 70 Years(2022) LAGE, Luis Alberto de Padua Covas; VITA, Rita Novello de; ALVES, Lucas Bassolli de Oliveira; JACOMASSI, Mayara D'Auria; CULLER, Hebert Fabricio; REICHERT, Cadiele Oliana; COSTA, Renata Oliveira; SIQUEIRA, Sheila Aparecida Coelho de; ROCHA, Vanderson; PEREIRA, Juliana
- Pathophysiology and molecular aspects of diffuse large B-cell lymphoma(2012) GOUVEIA, Gisele Rodrigues; SIQUEIRA, Sheila Aparecida Coelho; PEREIRA, JulianaDiffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma cases. Initially, the classification of non-Hodgkin lymphoma was based on morphology, but advances in immunology and molecular medicine allowed the introduction of a biological classification for these diseases. As for other cancers, non-Hodgkin lymphoma involves patterns of multi factorial pathogenesis with environmental factors, as well as genetic, occupational and dietary factors, contributing to its development. Multiple lesions involving molecular pathways of B-cell proliferation and differentiation may result in the activation of oncogenes such as the BCL2, BCL6,and MYC genes and the inactivation of tumor suppressor genes such as p53 and INK4, as well as other important transcription factors such as OCT-1 and OCT-2. A dramatic improvement in survival was seen after the recent introduction of the anti-CD20 monoclonal antibody. The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. However, 50% of all diffuse large B-Cell lymphoma patients remain incurable, creating a demand for more research with new advances in treatment. Thus, it is important to know and understand the key factors and molecular pathways involved in the pathogenesis of diffuse large B-Cell lymphoma.
conferenceObject 18 F-FDG PET Interim and Determination of Cellular Origin By Immunohistochemistry Identify a Group of Very Good Prognosis in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era(2014) LAGE, Luis Alberto de Padua Covas; COSTA, Renata Oliveira; HALLACK NETO, Abrahaeo Elias; SIQUEIRA, Sheila; SANTUCCI, Rodrigo; PAULA, Henrique Moura de; PEREIRA, JulianaconferenceObject Dysplastic Changes and Proliferation Index in Acquired Aplastic Anemia Are Not Associated with Progression to MDS/AML - a Study of Bone Marrow in Children and Adults Blood(2016) MARCHESI, Raquel Ferrari; VELLOSO, Elvira Deolinda Rodrigues Pereira; GARANITO, Marlene Pereira; KUMEDA, Cristina Aiko; SIQUEIRA, Sheila Aparecida Coelho; AZEVEDO NETO, Raymundo Soares; ZERBINI, Maria Claudia Nogueira